Status:
TERMINATED
Pilot Study of a Catheter-based Ultrasound Hyperthermia System
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Cervical Cancer
Prostate Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Ultrasound energy may be able to kill tumor cells by heating up the tumor cells with...
Detailed Description
OUTLINE: Patients undergo standard high-dose rate (HDR) brachytherapy. Approximately 2 hours after brachytherapy, patients undergo catheter-based ultrasound hyperthermia therapy over 60 minutes. Treat...
Eligibility Criteria
Inclusion
- Patients who are to be given HDR brachytherapy for treatment of solid tumor of the following:
- Cervical cancer Stage III or IV OR
- Prostate cancer (with rising prostate specific antigen after prior local therapy)
- Age \>=18 years
- Eligible for brachytherapy as determined per clinical standard of care.
- Ability to give written informed consent and willingness to comply with the requirements of the protocol
Exclusion
- Patients who are not candidates for HDR brachytherapy
- Any condition that compromises compliance with the objectives and procedures of this protocol, as judged by the principal investigator
Key Trial Info
Start Date :
December 18 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 23 2020
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00911079
Start Date
December 18 2009
End Date
July 23 2020
Last Update
July 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143-1708